Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Launches New R&D Organization
July 13, 2009
- GSK Drops SGLT2 Inhibitor Licensed from Kissei
July 13, 2009
- Korosho's Council Recommends Early Development of Plerixafor
July 6, 2009
- NEW PRODUCTS
July 6, 2009
- JSA Proposes Outline of Law on Measures against Stroke
July 6, 2009
- ExAblate 2000 Recommended for Approval for Treatment of Uterine Myoma
July 6, 2009
- GSK Makes Full Entry into Oncology Market with Tykerb
July 6, 2009
- ArBlast's Cultured Corneal Epithelial Cell Sheet Passes CDFS Committee
July 6, 2009
- Otsuka: Mainstay Products Drive Sales up to ¥440.4 Bil.
July 6, 2009
- 4 Med Materials Recommended for Health Insurance Coverage
July 6, 2009
- Bayer Moves Oncology Business Unit to Tokyo
July 6, 2009
- IP Injection of Paclitaxel Approved
July 6, 2009
- Blopress Keeps Top Place 5 Years in a Row
July 6, 2009
- New GL on COPD to Recommend β2 Stimulant + Inhaled Steroid Combinations
July 6, 2009
- FY2008 Sales of Ethical Drugs Up 2.9% to ¥8,368.6 Bil.: IMS Japan
July 6, 2009
- JSMI Introduces New Voluntary GL for Ad of OTC Drugs
July 6, 2009
- BUSINESS NEWS IN BRIEF
July 6, 2009
- Alogliptin Approval to Be Delayed at Least 2 Years: Takeda
July 6, 2009
- REGULATORY NEWS IN BRIEF
July 6, 2009
- Sandoz's Growth Hormone Approved as Japan's First Biosimilar
July 6, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…